✦ LIBER ✦

Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial

✍ Scribed by Sean C. Beinart; Paul Kolm; Emir Veledar; Zefeng Zhang; Elizabeth M. Mahoney; Olivier Bouin; Sylvie Gabriel; Joseph Jackson; Roland Chen; Jaime Caro; Steven Steinhubl; Eric Topol; William S. Weintraub

Book ID: 119265097
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 206 KB
Volume: 46
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2005.03.073

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-Term Cost Effectiveness of Early an

Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial

✍ S.C. Beinart; P. Kolm; E. Veledar 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Bleeding risk associated with 1 year of

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

✍ Herbert D. Aronow; Steven R. Steinhubl; Danielle M. Brennan; Peter B. Berger; Er 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Long-term cost-effectiveness of early an

Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation

✍ Elizabeth M. Mahoney; Shamir Mehta; Yong Yuan; Joseph Jackson; Roland Chen; Sylv 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 163 KB

The efficacy and safety of short- and lo

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial

✍ Patricia J.M. Best; Steven R. Steinhubl; Peter B. Berger; Arijit Dasgupta; Danie 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 231 KB